Peer-reviewedCC BYBiomedicines
Evaluation of FGD3 Expression in Advanced Prostate Cancer
4 affiliations
- 1Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, , 85-094 Bydgoszcz, Poland
- 2Department of Dermatology and Venerology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, , 85-094 Bydgoszcz, Poland;
- 3Department of Urology and Andrology, Ludwik Rydygier Collegium Medicum, , 85-094 Bydgoszcz, Poland;
- 4Department of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, , 85-094 Bydgoszcz, Poland;
Related
- A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer.
- Perioperative apalutamide in high-risk localized or locally advanced prostate cancer: Is PROTEUS trial practice changing?
- Balanced double aortic arch with late-onset symptoms detected on 18F-FDG PET/CT in an octogenarian with advanced prostate cancer : A case report
- Dual inhibition of p38α MAPK and Casein kinase δ/ϵ as a novel treatment strategy for AR-independent and taxane-resistant advanced prostate cancer
- Oral Targeted Therapies and Clinician Comanagement Among Men With Advanced Prostate Cancer
BibTeX
@article{malinowski2026evaluation,
title = {{Evaluation of FGD3 Expression in Advanced Prostate Cancer}},
author = {Bartosz Malinowski and Paulina Antosik and Layla Settaf-Cherif and Dariusz Grzanka and Michał Wiciński},
journal = {Biomedicines},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13702019},
note = {CC BY},
}
RIS
TY - JOUR
TI - Evaluation of FGD3 Expression in Advanced Prostate Cancer
AU - Bartosz Malinowski
AU - Paulina Antosik
AU - Layla Settaf-Cherif
AU - Dariusz Grzanka
AU - Michał Wiciński
PY - 2026
DA - 2026/10/01
JO - Biomedicines
UR - https://europepmc.org/article/PMC/PMC13702019
SN - 2227-9059
ER -